首页> 外文期刊>International journal of laboratory hematology >Quality assurance for point-of-care testing of oral anticoagulation: a large-scale evaluation of the Hemochron Junior Signature Microcoagulation System.
【24h】

Quality assurance for point-of-care testing of oral anticoagulation: a large-scale evaluation of the Hemochron Junior Signature Microcoagulation System.

机译:口腔抗凝即时检验的质量保证:Hemochron Junior Signature微凝系统的大规模评估。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We report the first large-scale evaluation of the Hemochron Junior Signature (HJS) Microcoagulation System for community monitoring of oral anticoagulation and establishment of a programme of internal and external quality assurance. Over 1600 HJS results, with a simultaneous venous sample for central analysis, were obtained over a 19 month period. Monitoring of an initial period of HJS results (n = 135) revealed an International Normalized Ratio (INR) over estimation (mean +1.05), with only 27% of results within 0.5 of the central laboratory INR. A correction factor was introduced which reduced the INR bias to +0.07 and improved the percentage of results within 0.5 of the central laboratory INR to 76% (n = 353). A revised correction factor was later introduced to adjust for an under estimation at higher INR values. This changed the INR bias to -0.05, with 76% of results within 0.5 of the central laboratory INR (n = 1174). Local external quality assurance samples were distributed monthly with a total of791 samples during the study period. 84% of test results were within 15% of the median value (range 73-97% per month). These results emphasize the value of a robust quality assurance programme when using point-of-care devices for community monitoring of oral anticoagulation.
机译:我们报告了首次对Hemochron Junior Signature(HJS)微凝系统进行的大规模评估,该系统可用于社区监测口服抗凝药并建立内部和外部质量保证计划。在19个月内获得了1600多个HJS结果,同时获得了用于中心分析的静脉样本。对HJS结果的初始阶段(n = 135)的监测显示,国际标准化比率(INR)高于估计值(平均值+1.05),只有27%的结果在中央实验室INR的0.5以内。引入了校正因子,可将INR偏倚降低至+0.07,并将结果百分比在中央实验室INR的0.5以内提高至76%(n = 353)。后来引入了修订的校正因子,以针对较高INR值下的估计不足进行调整。这将INR偏倚更改为-0.05,结果的76%处于中央实验室INR的0.5以内(n = 1174)。在研究期间,每月分发本地外部质量保证样本,总共791个样本。 84%的测试结果在中位数的15%以内(每月73-97%的范围)。这些结果强调了在使用现场护理设备进行社区口服抗凝监测时,强有力的质量保证计划的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号